Nduka Sunday Odunke, Okonta Eleje, Abba Chika Christiana, Ihekwereme Peter Chibueze, Ekwedigwe Uchenna, Okonta Matthew
Department of Clinical Pharmacy and Pharmacy Management, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.
Department of Clinical Pharmacy and Pharmacy Management, University of Nigeria, Nsukka, Enugu State, Nigeria.
Asian Pac J Trop Biomed. 2014 May;4(Suppl 1):S413-6. doi: 10.12980/APJTB.4.2014C400.
To evaluate the effect of Manix®, the commonly used polyherbal formulation on pefloxacin pharmacokinetic parameters.
Microbiological assay was employed using clinical isolate of Escherichia coli samples from hospitalized patients.
Manix® altered the bioavailability parameters of pefloxacin as thus, maximal concentration (Cmax) of pefloxacin (0.91±0.31) µg/mL occurred at time to reach maximal concentration (tmax) 4.0 h while in the group that received Manix® alongside pefloxacin Cmax was (0.22±0.08) µg/mL at tmax 1.0 h respectively. The area under curve of pefloxacin alone was (7.83±5.14) µg/h/mL while with Manix® was (2.60±0.08) µg/h/mL. There was a significant difference between Cmax, tmax and area under curve between pefloxacin alone and pefloxacin after Manix® pre-treatment (P<0.05).
The concurrent use of Manix® and pefloxacin has been found to compromise the therapeutic effectiveness of pefloxacin which could lead to poor clinical outcomes in patients.
评估常用的多草药配方制剂马尼克斯(Manix®)对培氟沙星药代动力学参数的影响。
采用微生物测定法,使用来自住院患者的大肠杆菌临床分离样本。
马尼克斯(Manix®)改变了培氟沙星的生物利用度参数,因此,培氟沙星的最大浓度(Cmax)为(0.91±0.31)μg/mL,达峰时间(tmax)为4.0小时,而在同时接受马尼克斯(Manix®)和培氟沙星的组中,Cmax分别为(0.22±0.08)μg/mL,tmax为1.0小时。单独使用培氟沙星时的曲线下面积为(7.83±5.14)μg/h/mL,与马尼克斯(Manix®)合用时为(2.60±0.08)μg/h/mL。单独使用培氟沙星与马尼克斯(Manix®)预处理后使用培氟沙星的Cmax、tmax和曲线下面积之间存在显著差异(P<0.05)。
已发现同时使用马尼克斯(Manix®)和培氟沙星会损害培氟沙星的治疗效果,这可能导致患者临床预后不良。